CB5064 Analogs

Novel Antifibrotic Peptides for ARDS Including COVID-19 Associated ARDS

Preclinical Update

December 2020

NASDAQ: CWBR

Forward Looking Statements

This presentation contains forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding our cash forecasts; anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the timing and progression of our CB4211 clinical trial, the expected timing of delivery of data, and the anticipated timing and progression of our other programs; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs and MBTs, including but not limited to the treatment of COVID-19 ARDS. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable than and that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; risks related to the impact on our business of the COVID-19 pandemic or similar public health crises; and our ability to establish and maintain partnerships with corporate and industry partners. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this presentation is made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

CB5064 Analogs: Demonstrate potential for treatment of COVID-19 ARDS in preliminary preclinical studies in mouse ARDS model

- **CB5064 Analogs origin:** Improved analogs of a natural peptide sequence encoded in the mitochondrial DNA
- **CB5064 Analogs selectively activate the apelin receptor:** A key signaling pathway known to be protective in animal models of ARDS, thrombosis, stroke, and sepsis
- **Rationale for COVID-19:** Based on published data, apelin signaling has potential to reduce COVID-19 ARDS mortality by simultaneously blocking many of the processes that lead to global damage and death
- **CB5064 Analogs are effective in a preclinical model of ARDS:** Reduced fluid accumulation, cytokine secretion, and neutrophil infiltration
- **Next steps:** Complete additional studies, candidate selection, scale up, and IND safety studies
- **Key Advisor:** Dr. Toby Maher, Director of Interstitial Lung Disease and Professor of Medicine at the Keck School of Medicine, University of Southern California



New Data: Single dose of CB5064 Analogs reduces lung fluid accumulation in mouse model of ARDS



Reduction in fluid accumulation:

- ARDS induced by lipopolysaccharide (LPS)
- Peptide dosed 1 hr before LPS injury
- Lung weight measured at 4 hours after LPS
- Reduced lung weight confirms previous data

Data are Mean +/- SEM. *P<0.05, ***P<0.001, vs LPS/vehicle.

New Data: Single dose of CB5064 Analogs before LPS injury reduces secretion of key pro-inflammatory cytokines in mouse model of ARDS



Broad reduction in cytokine secretion: Reduced levels of key mediators of cytokine storm

Data are Mean +/- SEM. *P<0.05, **P<0.01 vs LPS/vehicle.